Accolades
Lei Li Named “Life Sciences and Healthcare Lawyer of the Year”
December 8, 2023
Lei Li has been honored as the “Life Sciences and Healthcare Lawyer of the Year” at The Legal 500 China Awards 2023. The awards recognize the “leading firms and lawyers together with the younger rising talent who are part of China’s extensive and complex legal market.”
Lei Li is the Managing Partner of Sidley’s Shanghai and Beijing offices. He advises clients on a broad range of regulatory, compliance, and government enforcement matters in China, with a particular focus on the life sciences industry and is one of the most accoladed legal practitioners in China in his areas of practice. Lei has advised multinational and local Chinese pharmaceutical and medical device companies on matters across the full spectrum of the industry and has handled some of the largest and most representative matters in the industry in China in the last decade.
Lei Li is the Managing Partner of Sidley’s Shanghai and Beijing offices. He advises clients on a broad range of regulatory, compliance, and government enforcement matters in China, with a particular focus on the life sciences industry and is one of the most accoladed legal practitioners in China in his areas of practice. Lei has advised multinational and local Chinese pharmaceutical and medical device companies on matters across the full spectrum of the industry and has handled some of the largest and most representative matters in the industry in China in the last decade.
Contacts
Offices
Capabilities
Suggested News & Insights
EU Pharma Package: Sharp New Tools With Limited ProtectionsDecember 18, 2025First Chair Trial and Leading Product Liability Lawyer Paul Boehm Joins Sidley as Partner in D.C. to Expand Product Liability and Mass Torts Litigation PracticeDecember 18, 2025EU Biotech Act: EU Proposes First Set of Rules to Facilitate Biopharmaceutical CompetitivenessThursday, December 18, 2025Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease TherapyDecember 18, 2025Sidley Secures Plan Confirmation in Prospect Medical Holdings' US$2.3 Billion Chapter 11 CaseDecember 17, 2025Sidley Represents Apollo Funds in Majority Investment in Prosol GroupDecember 16, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
